Loading
Latest filing published 02 Mar 2022 for Aarti Drugs Limited, €3,046.
Uday Moreshwar Patil (chief executive) discloses dealings in Aarti Drugs Limited to SEBI (PIT + SAST). Between 18 May 2021 and 28 February 2022, the trades on record add up to 5 filings.
The open-market record is one-sided, with 4 purchases worth €8,908 and not one sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. In 2022 alone, the filings show 4 purchases and no sales.
A typical purchase (the median) is worth €2,869. Clusters matter here: 4 out of 4 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.
The latest filing, published on 2 March 2022, reports an open-market purchase of €3,046 in Aarti Drugs Limited. Every figure here comes from the filings published by SEBI (PIT + SAST) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations